Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $176M (up 37.9% year over year) with net income of −$67M.
Q2 2026 key financials · XBRL
- Revenue
- $176M
- +37.9% YoY · +10.2% QoQ
- Net income
- −$67M
- −1047.0% YoY · +91.5% QoQ
- Operating margin
- -24.1%
- EPS (diluted)
- −$0.60
- −400.0% YoY · +95.5% QoQ
Source: XBRL data from the Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 10-Q on SEC EDGAR. USD.
Mirum Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $176.2M, up $48.5M YoY from $127.8M
- Livmarli best performer: $128.7M, up $40.6M YoY
- Bile Acid Medicines: $47.5M, up $7.9M YoY
- Operating loss $42.5M vs $5.0M; operating margin -24.1% vs -3.9% YoY
- Cash, equivalents and investments $561.3M vs $391.4M at December 31, 2025; continued net losses expected
Risk Factors
- No newly added risk factor or explicit quarter-over-quarter change identified in the provided excerpt
- EU Health Technology Assessment Regulation expanded to orphan medicines in January 2028 and all centrally authorized medicines in 2030
- Medicaid rebate compliance exposure, including civil monetary penalties for late AMP and best-price submissions
- Volixibat gastrointestinal and liver-safety concerns, including diarrhea in 77% of PBC VANTAGE patients
- Medicare and commercial-payor cost containment threatening coverage, reimbursement, and pricing for approved medicines
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mirum Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.